InBody Co.,Ltd (041830.KQ)
KRW 24150.0
(-0.21%)
KRW 24150.0
(-0.21%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 36.72 Billion KRW | 8.6% |
| 2022 | 33.81 Billion KRW | -0.64% |
| 2021 | 34.03 Billion KRW | 94.28% |
| 2020 | 17.51 Billion KRW | -14.25% |
| 2019 | 20.42 Billion KRW | 3.85% |
| 2018 | 19.67 Billion KRW | 1.81% |
| 2017 | 19.32 Billion KRW | 13.75% |
| 2016 | 16.98 Billion KRW | -1.87% |
| 2015 | 17.31 Billion KRW | 94.96% |
| 2014 | 8.87 Billion KRW | 43.34% |
| 2013 | 6.19 Billion KRW | 9.78% |
| 2012 | 5.64 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 8.79 Billion KRW | 20.9% |
| 2024 Q2 | 8.3 Billion KRW | -5.64% |
| 2023 Q2 | 7.04 Billion KRW | -31.92% |
| 2023 Q1 | 10.34 Billion KRW | 74.52% |
| 2023 FY | 36.72 Billion KRW | 8.6% |
| 2023 Q3 | 12.05 Billion KRW | 71.07% |
| 2023 Q4 | 7.27 Billion KRW | -39.63% |
| 2022 Q3 | 9.2 Billion KRW | 6.67% |
| 2022 Q1 | 10.05 Billion KRW | 17.16% |
| 2022 FY | 33.81 Billion KRW | -0.64% |
| 2022 Q4 | 5.92 Billion KRW | -35.58% |
| 2022 Q2 | 8.62 Billion KRW | -14.15% |
| 2021 Q4 | 8.57 Billion KRW | 21.35% |
| 2021 Q1 | 10.04 Billion KRW | 60.11% |
| 2021 FY | 34.03 Billion KRW | 94.28% |
| 2021 Q2 | 8.33 Billion KRW | -17.0% |
| 2021 Q3 | 7.06 Billion KRW | -15.22% |
| 2020 Q1 | 4.94 Billion KRW | 52.21% |
| 2020 Q3 | 5.89 Billion KRW | 1364.66% |
| 2020 Q4 | 6.27 Billion KRW | 6.43% |
| 2020 FY | 17.51 Billion KRW | -14.25% |
| 2020 Q2 | 402.52 Million KRW | -91.86% |
| 2019 Q4 | 3.24 Billion KRW | -34.54% |
| 2019 Q3 | 4.96 Billion KRW | -27.14% |
| 2019 FY | 20.42 Billion KRW | 3.85% |
| 2019 Q1 | 5.4 Billion KRW | 35.66% |
| 2019 Q2 | 6.81 Billion KRW | 26.04% |
| 2018 Q1 | 3.67 Billion KRW | -40.99% |
| 2018 Q3 | 5.98 Billion KRW | -0.61% |
| 2018 Q2 | 6.02 Billion KRW | 63.81% |
| 2018 FY | 19.67 Billion KRW | 1.81% |
| 2018 Q4 | 3.98 Billion KRW | -33.45% |
| 2017 FY | 19.32 Billion KRW | 13.75% |
| 2017 Q4 | 6.23 Billion KRW | 8.27% |
| 2017 Q2 | 4.9 Billion KRW | 102.01% |
| 2017 Q1 | 2.42 Billion KRW | -44.98% |
| 2017 Q3 | 5.75 Billion KRW | 17.27% |
| 2016 Q4 | 4.41 Billion KRW | 42.05% |
| 2016 FY | 16.98 Billion KRW | -1.87% |
| 2016 Q3 | 3.1 Billion KRW | -32.76% |
| 2016 Q2 | 4.62 Billion KRW | -4.55% |
| 2016 Q1 | 4.84 Billion KRW | 13.12% |
| 2015 Q4 | 4.28 Billion KRW | -21.03% |
| 2015 FY | 17.31 Billion KRW | 94.96% |
| 2015 Q1 | 3.79 Billion KRW | 392.01% |
| 2015 Q2 | 3.81 Billion KRW | 0.58% |
| 2015 Q3 | 5.42 Billion KRW | 42.03% |
| 2014 Q1 | 3.37 Billion KRW | 220.56% |
| 2014 Q2 | 2.5 Billion KRW | -25.75% |
| 2014 Q3 | 2.23 Billion KRW | -10.78% |
| 2014 Q4 | 771.13 Million KRW | -65.47% |
| 2014 FY | 8.87 Billion KRW | 43.34% |
| 2013 Q1 | 2.5 Billion KRW | 522.2% |
| 2013 Q4 | 1.05 Billion KRW | -26.72% |
| 2013 FY | 6.19 Billion KRW | 9.78% |
| 2013 Q2 | 1.2 Billion KRW | -52.06% |
| 2013 Q3 | 1.43 Billion KRW | 19.47% |
| 2012 Q3 | 1.24 Billion KRW | 0.0% |
| 2012 Q4 | 402.74 Million KRW | -67.7% |
| 2012 FY | 5.64 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 116.43 Billion KRW | 68.461% |
| Curexo Inc. | -4.85 Billion KRW | 856.233% |
| Seegene, Inc. | 669.01 Million KRW | -5389.115% |
| i-SENS, Inc. | 3.7 Billion KRW | -890.084% |
| Ray Co., Ltd. | -2.14 Billion KRW | 1810.967% |
| Gencurix Inc. | -19.26 Billion KRW | 290.669% |
| Sugentech Inc. | -17.23 Billion KRW | 313.031% |
| L&C Bio Co., Ltd | 48.36 Billion KRW | 24.065% |